Literature DB >> 16968899

Efficiency of T-cell receptor expression in dual-specific T cells is controlled by the intrinsic qualities of the TCR chains within the TCR-CD3 complex.

Mirjam H M Heemskerk1, Renate S Hagedoorn, Menno A W G van der Hoorn, Lars T van der Veken, Manja Hoogeboom, Michel G D Kester, Roel Willemze, J H Frederik Falkenburg.   

Abstract

Genetic engineering of T lymphocytes is an attractive strategy to specifically redirect T-cell immunity toward viral infections and malignancies. We previously demonstrated redirected antileukemic reactivity of cytomegalovirus (CMV)-specific T cells by transfer of minor histocompatibility antigen HA-2-specific T-cell receptors (TCRs). HA-2-TCR-transferred CMV-specific T cells were potent effectors against HA-2-expressing leukemic cells, as well as CMV-expressing cells. Functional activity of these T cells correlated with TCR cell-surface expression. In the present study we analyzed which properties of transferred and endogenous TCRs are crucial for efficient cell-surface expression. We demonstrate that expression of the introduced TCR is not a random process but is determined by characteristics of both the introduced and the endogenously expressed TCR. The efficiency of TCR cell-surface expression is controlled by the intrinsic quality of the TCR complex. In addition, we demonstrate that chimeric TCRs can be formed and that efficiency of TCR expression is independent of whether TCRs are retrovirally introduced or naturally expressed. In conclusion, introduced, endogenous, and chimeric TCRs compete for cell-surface expression in favor of the TCR-CD3 complex with best-pairing properties.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16968899     DOI: 10.1182/blood-2006-03-013318

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  70 in total

1.  Mixed T cell receptor dimers harbor potentially harmful neoreactivity.

Authors:  Marleen M van Loenen; Renate de Boer; Avital L Amir; Renate S Hagedoorn; Gerdien L Volbeda; Roelof Willemze; Johannes J van Rood; J H Frederik Falkenburg; Mirjam H M Heemskerk
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-01       Impact factor: 11.205

2.  Optimization of the HA-1-specific T-cell receptor for gene therapy of hematologic malignancies.

Authors:  Marleen M van Loenen; Renate de Boer; Renate S Hagedoorn; Esther H M van Egmond; J H Frederik Falkenburg; Mirjam H M Heemskerk
Journal:  Haematologica       Date:  2010-11-25       Impact factor: 9.941

Review 3.  New Strategies in Engineering T-cell Receptor Gene-Modified T cells to More Effectively Target Malignancies.

Authors:  Thomas M Schmitt; Ingunn M Stromnes; Aude G Chapuis; Philip D Greenberg
Journal:  Clin Cancer Res       Date:  2015-10-13       Impact factor: 12.531

4.  Single-chain VαVβ T-cell receptors function without mispairing with endogenous TCR chains.

Authors:  D H Aggen; A S Chervin; T M Schmitt; B Engels; J D Stone; S A Richman; K H Piepenbrink; B M Baker; P D Greenberg; H Schreiber; D M Kranz
Journal:  Gene Ther       Date:  2011-07-14       Impact factor: 5.250

5.  T-cell receptor gene transfer for the treatment of leukemia and other tumors.

Authors:  Mirjam H M Heemskerk
Journal:  Haematologica       Date:  2010-01       Impact factor: 9.941

6.  High-throughput identification of antigen-specific TCRs by TCR gene capture.

Authors:  Carsten Linnemann; Bianca Heemskerk; Pia Kvistborg; Roelof J C Kluin; Dmitriy A Bolotin; Xiaojing Chen; Kaspar Bresser; Marja Nieuwland; Remko Schotte; Samira Michels; Raquel Gomez-Eerland; Lorenz Jahn; Pleun Hombrink; Nicolas Legrand; Chengyi Jenny Shu; Ilgar Z Mamedov; Arno Velds; Christian U Blank; John B A G Haanen; Maria A Turchaninova; Ron M Kerkhoven; Hergen Spits; Sine Reker Hadrup; Mirjam H M Heemskerk; Thomas Blankenstein; Dmitriy M Chudakov; Gavin M Bendle; Ton N M Schumacher
Journal:  Nat Med       Date:  2013-10-13       Impact factor: 53.440

Review 7.  Immunomodulation in the treatment of haematological malignancies.

Authors:  Michela Cesco-Gaspere; Emma Morris; Hans J Stauss
Journal:  Clin Exp Med       Date:  2009-02-24       Impact factor: 3.984

8.  Subtle affinity-enhancing mutations in a myelin oligodendrocyte glycoprotein-specific TCR alter specificity and generate new self-reactivity.

Authors:  Akshata Udyavar; Rajshekhar Alli; Phuong Nguyen; Lesley Baker; Terrence L Geiger
Journal:  J Immunol       Date:  2009-04-01       Impact factor: 5.422

9.  Influenza virus-specific TCR-transduced T cells as a model for adoptive immunotherapy.

Authors:  Belinda Berdien; Henrike Reinhard; Sabrina Meyer; Stefanie Spöck; Nicolaus Kröger; Djordje Atanackovic; Boris Fehse
Journal:  Hum Vaccin Immunother       Date:  2013-02-21       Impact factor: 3.452

10.  CD34-based enrichment of genetically engineered human T cells for clinical use results in dramatically enhanced tumor targeting.

Authors:  Håkan Norell; Yi Zhang; James McCracken; Telma Martins da Palma; Aaron Lesher; Yueying Liu; Jeffrey J Roszkowski; Anquanette Temple; Glenda G Callender; Timothy Clay; Rimas Orentas; José Guevara-Patiño; Michael I Nishimura
Journal:  Cancer Immunol Immunother       Date:  2010-01-06       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.